IMMUNE NETW 2020 10.4110/in.2020.20.e48
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181
Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
Lee1, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM

LANCET RESPIR MED 2020 10.1016/S2213-2600(20)30154-5
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study) an open-label, phase 1b/2, multicentre, randomised trial
Wu1, YL; Cheng, Y; Zhou, JY; Lu, S; Zhang, YP; Zhao, J; Kim, DW; Soo, RA; Kim, SW; Pan, HM; Chen, YM; Chian, CF; Liu, XQ; Tan, DSW; Bruns, R; Straub, J; Johne, A; Scheele, J; Park, K; Yang, JCH

SCI REP-UK 2020 10.1038/s41598-020-76130-1
Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Koh1, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

FUTURE ONCOL 2020 10.2217/fon-2020-0935
Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer
Solomon1, BJ; Zhou, CC; Drilon, A; Park, K; Wolf, J; Elamin, Y; Davis, HM; Soldatenkova, V; Sashegyi, A; Lin, AB; Lin, BK; Loong, HHF; Novello, S; Arriola, E; Perol, M; Goto, K; Santini, FC

J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

BIOLOGY-BASEL 2020 10.3390/biology9100326
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?
Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

FRONT ONCOL 2020 10.3389/fonc.2020.578756
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy JUNIPER
Goldman1, JW; Mazieres, J; Barlesi, F; Dragnev, KH; Koczywas, M; Goskel, T; Cortot, AB; Girard, N; Wesseler, C; Bischoff, H; Nadal, E; Park, K; Lu, S; Taus, A; Cobo, M; Estrem, ST; Wijayawardana, SR; Turner, K; Oakley, GJ; Hurt, KC; Chiang, AY; Hossain, AM; John, WJ; Paz-Ares, L

J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

CANCER SCI 2020 10.1111/cas.14655
Ramucirumab or placebo plus erlotinib inEGFR-mutated, metastatic non-small-cell lung cancer East Asian subset of RELAY
Nishio1, M; Seto, T; Reck, M; Garon, EB; Chiu, CH; Yoh, K; Imamura, F; Park, K; Shih, JY; Visseren-Grul, C; Frimodt-Moller, B; Zimmermann, A; Homma, G; Enatsu, S; Nakagawa, K

CANCER RES TREAT 2020 10.4143/crt.2020.278
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

ANN ONCOL 2020 10.1016/j.annonc.2020.06.017
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NEW ENGL J MED 2020 10.1056/NEJMoa1917239
KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors
Hong1, DS; Fakih, MG; Strickler, JH; Desai, J; Durm, GA; Shapiro, GI; Falchook, GS; Price, TJ; Sacher, A; Denlinger, CS; Bang, YJ; Dy, GK; Krauss, JC; Kuboki, Y; Kuo, JC; Coveler, AL; Park, K; Kim, TW; Barlesi, F; Munster, PN; Ramalingam, SS; Burns, TF; Meric-Bernstam, F; Henary, H; Ngang, J; Ngarmchamnanrith, G; Kim, J; Houk, BE; Canon, J; Lipford, JR; Friberg, G; Lito, P; Govindan, R; Li, BT

SCI REP-UK 2020 10.1038/s41598-020-72096-2
Integrative genomic analysis of salivary duct carcinoma
Kim1, Y; Song, S; Lee, M; Swatloski, T; Kang, JH; Ko, YH; Park, WY; Jeong, HS; Park, K

CANCER 2020 10.1002/cncr.33048
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy
Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

LUNG CANCER 2020 10.1016/j.lungcan.2020.06.032
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC The phase II ATLANTIC study
Garassino1, MC; Cho, BC; Kim, JH; Mazieres, J; Vansteenkiste, J; Lena, H; Jaime, JC; Gray, JE; Powderly, J; Chouaid, C; Bidoli, P; Wheatley-Price, P; Park, K; Soo, RA; Poole, L; Wadsworth, C; Dennis, PA; Rizvi, NA

EUR J CANCER 2020 10.1016/j.ejca.2020.06.007
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma An open-label, phase Ia/b study (JVDJ)
Bang1, YJ; Golan, T; Dahan, L; Fu, SQ; Moreno, V; Park, K; Geva, R; De Braud, F; Wainberg, ZA; Reck, M; Goff, L; Laing, N; Mi, G; Oliveira, JM; Wasserstrom, H; Lin, CC

BMC CANCER 2020 10.1186/s12885-020-07214-4
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea
Kim1, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ

SCI REP-UK 2020 10.1038/s41598-020-70168-x
Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations
Kim1, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033
Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)
Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K

NEW ENGL J MED 2020 10.1056/NEJMoa2005653
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
Drilon1, A; Oxnard, GR; Tan, DSW; Loong, HHF; Johnson, M; Gainor, J; McCoach, CE; Gautschi, O; Besse, B; Cho, BC; Peled, N; Weiss, J; Kim, YJ; Ohe, Y; Nishio, M; Park, K; Patel, J; Seto, T; Sakamoto, T; Rosen, E; Shah, MH; Barlesi, F; Cassier, PA; Bazhenova, L; De Braud, F; Garralda, E; Velcheti, V; Satouchi, M; Ohashi, K; Pennell, NA; Reckamp, KL; Dy, GK; Wolf, J; Solomon, B; Falchook, G; Ebata, K; Nguyen, M; Nair, B; Zhu, EY; Yang, L; Huang, X; Olek, E; Rothenberg, SM; Goto, K; Subbiah, V

EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932
Evaluating entrectinib as a treatment option for non-small cell lung cancer
Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC DIS 2020 10.21037/jtd.2019.08.29
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ANN ONCOL 2020 10.1016/j.annonc.2020.04.004
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

EUR J CANCER 2020 10.1016/j.ejca.2020.03.029
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CANCER 2020 10.1002/cncr.32809
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

THER ADV MED ONCOL 2020 10.1177/1758835920926796
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J

NAT COMMUN 2020 10.1038/s41467-020-16164-1
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

ANN ONCOL 2020 10.1016/j.annonc.2020.02.006
ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer
Planchard1, D; Reinmuth, N; Orlov, S; Fischer, JR; Sugawara, S; Mandziuk, S; Marquez-Medina, D; Novello, S; Takeda, Y; Soo, R; Park, K; McCleod, M; Geater, SL; Powell, M; May, R; Scheuring, U; Stockman, P; Kowalski, D

IN VIVO 2020 10.21873/invivo.11920
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests
Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Journal of thoracic disease 2020 10.21037/jtd.2020.03.23
Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
Shin1, S; Kim, HK; Cho, JH; Choi, YS; Kim, K; Kim, J; Zo, JI; Sun, JM; Ahn, MJ; Park, K; Pyo, H; Ahn, YC; Shim, YM

J THORAC ONCOL 2020 10.1016/j.jtho.2019.12.126
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Yang1, JCH; Schuler, M; Popat, S; Miura, S; Heeke, S; Park, K; Marten, A; Kim, ES

INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2020 10.1016/j.jtho.2019.11.006
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
Nishio1, M; Felip, E; Orlov, S; Park, K; Yu, CJ; Tsai, CM; Cobo, M; McKeage, M; Su, WC; Mok, T; Scagliotti, GV; Spigel, DR; Viraswami-Appanna, K; Chen, Z; Passos, VQ; Shaw, AT

J THORAC ONCOL 2020 10.1016/j.jtho.2020.01.016
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Poirier1, JT; George, J; Owonikoko, TK; Berns, A; Brambilla, E; Byers, LA; Carbone, D; Chen, HJ; Christensen, CL; Dive, C; Farago, AF; Govindan, R; Hann, C; Hellmann, MD; Horn, L; Johnson, JE; Ju, YS; Kang, SM; Krasnow, M; Lee, J; Lee, SH; Lehman, J; Lok, B; Lovly, C; MacPherson, D; McFadden, D; Minna, J; Oser, M; Park, K; Park, KS; Pommier, Y; Quaranta, V; Ready, N; Sage, J; Scagliotti, G; Sos, ML; Sutherland, KD; Travis, WD; Vakoc, CR; Wait, SJ; Wistuba, I; Wong, KK; Zhang, H; Daigneault, J; Wiens, J; Rudin, CM; Oliver, TG

BRIT J CANCER 2020 10.1038/s41416-020-0802-1
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
Hong1, DVS; Kang, YK; Borad, M; Sachdev, J; Ejadi, S; Lim, HY; Brenner, AJ; Park, K; Lee, JL; Kim, TY; Shin, S; Becerra, CR; Falchook, G; Stoudemire, J; Martin, D; Kelnar, K; Peltier, H; Bonato, V; Bader, AG; Smith, S; Kim, S; O'Neill, V; Beg, MS

NAT GENET 2020 10.1038/s41588-019-0557-x
Comprehensive molecular characterization of mitochondrial genomes in human cancers
Yuan1, Y; Ju, YS; Kim, Y; Li, J; Wang, YM; Yoon, CJ; Yang, Y; Martincorena, I; Creighton, CJ; Weinstein, JN; Xu, YX; Han, L; Kim, HL; Nakagawa, H; Park, K; Campbell, PJ; Liang, H

J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015
Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology
Shin1, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

NATURE 2020 10.1038/s41586-020-1969-6
Pan-cancer analysis of whole genomes
Campbell1, PJ; Getz, G; Korbel, JO; Stuart, JM; Jennings, JL; Stein, LD; Perry, MD; Nahal-Bose, HK; Ouellette, BFF; Li, CH; Rheinbay, E; Nielsen, GP; Sgroi, DC; Wu, CL; Faquin, WC; Deshpande, V; Boutros, PC; Lazar, AJ; Hoadley, KA; Louis, DN; Dursi, LJ; Yung, CK; Bailey, MH; Saksena, G; Raine, KM; Buchhalter, I; Kleinheinz, K; Schlesner, M; Zhang, J; Wang, W; Wheeler, DA; Ding, L; Simpson, JT; O'Connor, BD; Yakneen, S; Ellrott, K; Miyoshi, N; Butler, AP; Royo, R; Shorser, SI; Vazquez, M; Rausch, T; Tiao, G; Waszak, SM; Rodriguez-Martin, B; Shringarpure, S; Wu, DY; Demidov, GM; Delaneau, O; Hayashi, S; Imoto, S; Habermann, N; Segre, AV; Garrison, E; Cafferkey, A; Alvarez, EG; Heredia-Genestar, JM; Muyas, F; Drechsel, O; Bruzos, AL; Temes, J; Zamora, J; Baez-Ortega, A; Kim, HL; Mashl, RJ; Ye, K; DiBiase, A; Huang, KL; Letunic, I; McLellan, MD; Newhouse, SJ; Shmaya, T; Kumar, S; Wedge, DC; Wright, MH; Yellapantula, VD; Gerstein, M; Khurana, E; Marques-Bonet, T; Navarro, A; Bustamante, CD;

COMMUN BIOL 2020 10.1038/s42003-019-0741-7
Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis
Carlevaro-Fita1, J; Lanzos, A; Feuerbach, L; Hong, C; Mas-Ponte, D; Pedersen, JS; Johnson, R; Abascal, F; Amin, SB; Bader, GD; Barenboim, J; Beroukhim, R; Bertl, J; Boroevich, KA; Brunak, S; Campbell, PJ; Carlevaro-Fita, J; Chakravarty, D; Chan, CWY; Chen, K; Choi, JK; Deu-Pons, J; Dhingra, P; Diamanti, K; Feuerbach, L; Fink, JL; Fonseca, NA; Frigola, J; Gambacorti-Passerini, C; Garsed, DW; Gerstein, M; Getz, G; Gonzalez-Perez, A; Guo, QY; Gut, IG; Haan, D; Hamilton, MP; Haradhvala, NJ; Harmanci, AO; Helmy, M; Herrmann, C; Hess, JM; Hobolth, A; Hodzic, E; Hong, C; Hornshoj, H; Isaev, K; Izarzugaza, JMG; Johnson, TA; Juul, M; Juul, RI; Kahles, A; Kahraman, A; Kellis, M; Khurana, E; Kim, J; Kim, JK; Kim, Y; Komorowski, J; Korbel, JO; Kumar, S; Lanzos, A; Larsson, E; Lawrence, MS; Lee, D; Lehmann, KV; Li, ST; Li, XT; Lin, Z; Liu, EM; Lochovsky, L; Lou, SK; Madsen, T; Marchal, K; Martincorena, I; Martinez-Fundichely, A; Maruvka, YE; McGillivray, PD; Meyerson, W; Muinos, F; Mularoni, L; Naka

TARGET ONCOL 2020 10.1007/s11523-020-00701-5
Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study
Kato1, H; de Souza, P; Kim, SW; Lickliter, JD; Naito, Y; Park, K; Kumar, S; Mugundu, GM; Bang, YJ

Cancer Med 2020 10.1002/cam4.2868
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence
Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ANN ONCOL 2020 10.1016/j.annonc.2019.10.026
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Park1, K; Vansteenkiste, J; Lee, KH; Pentheroudakis, G; Zhou, C; Prabhash, K; Seto, T; Voon, PJ; Tan, DSW; Yang, JCH; Wang, J; Babu, KG; Nakayama, Y; Alip, A; Chua, KLM; Cheng, JCH; Senan, S; Ahn, YC; Kim, TY; Ahn, HK; Peters, S; Yoshino, T; Douillard, JY

NATURE 2020 10.1038/s41586-020-1965-x
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
Rheinbay1, E; Nielsen, MM; Abascal, F; Wala, JA; Shapira, O; Tiao, G; Hornshoj, H; Hess, JM; Juul, RI; Lin, Z; Feuerbach, L; Sabarinathan, R; Madsen, T; Kim, J; Mularoni, L; Shuai, S; Lanz?s, A; Herrmann, C; Maruvka, YE; Shen, C; Amin, SB; Bandopadhayay, P; Bertl, J; Boroevich, KA; Busanovich, J; Carlevaro-Fita, J; Chakravarty, D; Chan, CWY; Craft, D; Dhingra, P; Diamanti, K; Fonseca, NA; Gonzalez-Perez, A; Guo, QY; Hamilton, MP; Haradhvala, NJ; Hong, C; Isaev, K; Johnson, TA; Juul, M; Kahles, A; Kahraman, A; Kim, Y; Komorowski, J; Kumar, K; Kumar, S; Lee, D; Lehmann, KV; Li, Y; Liu, EM; Lochovsky, L; Park, K; Pich, O; Roberts, ND; Saksena, G; Schumacher, SE; Sidiropoulos, N; Sieverling, L; Sinnott-Armstrong, N; Stewart, C; Tamborero, D; Tubio, JMC; Umer, HM; Uusk?la-Reimand, L; Wadelius, C; Wadi, L; Yao, XT; Zhang, CZ; Zhang, J; Haber, JE; Hobolth, A; Imielinski, M; Kellis, M; Lawrence, MS; von Mering, C; Nakagawa, H; Raphael, BJ; Rubin, MA; Sander, C; Stein, LD; Stuart, JM; Tsunoda, T

J CLIN ONCOL 2020 10.1200/JCO.19.00931
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CURR MED RES OPIN 2020 10.1080/03007995.2019.1676708
Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis
Cho1, BC; Kim, DW; Park, K; Lee, JS; Yoo, SS; Kang, JH; Lee, SY; Kim, CH; Jang, SH; Kim, YC; Yoon, HK; Han, JY; Kim, SW

CANCER RES TREAT 2020 10.4143/crt.2019.186
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

HEAD NECK-J SCI SPEC 2020 10.1002/hed.26067
Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review
Lee1, T; Cho, J; Baek, CH; Son, YI; Jeong, HS; Chung, MK; Hong, SD; Ahn, YC; Oh, DR; Noh, JM; Park, K; Ahn, MJ; Kim, HJ; Kim, YK; Ko, YH

BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

Oncoimmunology 2020 10.1080/2162402X.2020.1722023
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

RESP RES 2020 10.1186/s12931-019-1254-0
Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer
Shin1, S; Choi, YS; Jung, JJ; Im, Y; Shin, SH; Kang, D; Cho, JH; Kim, HK; Kim, J; Zo, JI; Shim, YM; Park, K; Ahn, MJ; Ahn, YC; Lee, G; Cho, J; Lee, HY; Park, HY

J THORAC ONCOL 2019 10.1016/j.jtho.2019.10.010
In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing
Park1, S; Lee, SH; Park, K

LANCET ONCOL 2019 10.1016/S1470-2045(19)30634-5
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Nakagawa1, K; Garon, EB; Seto, T; Nishio, M; Aix, SP; Paz-Ares, L; Chiu, CH; Park, K; Novello, S; Nadal, E; Imamura, F; Yoh, K; Shih, JY; Au, KH; Moro-Sibilot, D; Enatsu, S; Zimmermann, A; Frimodt-Moller, B; Visseren-Grul, C; Reck, M

INT J CANCER 2019 10.1002/ijc.32235
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease
Shin1, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.234
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Kim1, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ

NAT COMMUN 2019 10.1038/s41467-019-12159-9
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

LUNG CANCER 2019 10.1016/j.lungcan.2019.07.007
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
Kim1, DW; Lee, DH; Han, JY; Lee, J; Cho, BC; Kang, JH; Lee, KH; Cho, EK; Kim, JS; Min, YJ; Cho, JY; An, HJ; Kim, HG; Lee, KH; Kim, BS; Jang, IJ; Yoon, S; Han, O; Noh, YS; Hong, KY; Park, K

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

SCI REP-UK 2019 10.1038/s41598-019-48674-4
Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
Moon1, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

ONCOLOGIST 2019 10.1634/theoncologist.2018-0695
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist1, LV; Gray, JE; Harb, WA; Lopez-Chavez, A; Doebele, RC; Modiano, MR; Jackman, DM; Baggstrom, MQ; Atmaca, A; Felip, E; Provencio, M; Cobo, M; Adiwijaya, B; Kuesters, G; Kamoun, WS; Andreas, K; Pipas, JM; Santillana, S; Cho, BC; Park, K; Shepherd, FA

LUNG CANCER 2019 10.1016/j.lungcan.2019.04.006
First-line afatinib for advanced EGFRm plus NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Schuler1, M; Paz-Ares, L; Sequist, LV; Hirsh, V; Lee, KH; Wu, YL; Lu, S; Zho, CC; Feng, JF; Ellis, SH; Samuelsen, CH; Tang, WB; Marten, A; Ehrnrooth, E; Park, K; Yang, JCH

J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.002
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Cho1, BC; Obermannova, R; Bearz, A; McKeage, M; Kim, DW; Batra, U; Borra, G; Orlov, S; Kim, SW; Geater, SL; Postmus, PE; Laurie, SA; Park, K; Yang, CT; Ardizzoni, A; Bettini, AC; de Castro, G; Kiertsman, F; Chen, Z; Lau, YY; Viraswami-Appanna, K; Passos, VQ; Dziadziuszko, R

LUNG CANCER 2019 10.1016/j.lungcan.2019.04.014
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Park1, K; Bennouna, J; Boyer, M; Hida, T; Hirsh, V; Kato, T; Lug, S; Mok, T; Nakagawa, K; O'Byrne, K; Paz-Ares, L; Schuler, M; Sibilotru, DM; Tan, EH; Tanaka, H; We, YL; Yang, JCH; Zhang, L; Zhou, CC; Marten, A; Tang, WB; Yamamoto, N

J CANCER RES CLIN 2019 10.1007/s00432-019-02862-x
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Schuler1, M; Tan, EH; O'Byrne, K; Zhang, L; Boyer, M; Mok, T; Hirsh, V; Yang, JCH; Lee, KH; Lu, S; Shi, YK; Kim, SW; Laskin, J; Kim, DW; Arvis, CD; Kolbeck, K; Massey, D; Marten, A; Paz-Ares, L; Park, K

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.021
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients
Da Nam1, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS